Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.

Authors

Madiha Naseem

Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA

Madiha Naseem , Shu Cao , Sebastian Stintzing , Francesca Battaglin , Ryuma Tokunaga , Alberto Puccini , Martin D. Berger , Shivani Soni , Wu Zhang , Afsaneh Barzi , Volker Heinemann , Heinz-Josef Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.

First Author: Madiha Naseem

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.

First Author: Pooja Mittal

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.

First Author: Ilse Van Oostrum

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.

First Author: Sebastian Stintzing